MARKET WIREYahoo! Finance Canada • 1d ago
Cingulate Inc. (CING) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
Why CING Stock advanced +1.00% Today — RQD Quant Desk Flash
$5.03 +1.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.03
Cingulate Inc. (CING) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $73.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CING Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CING stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Cingulate Inc. (NASDAQ: CING) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $5.03 (+1.00% 1D, market cap $73.1M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CING ranks #640 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CING compare to LFVN and MNOV in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CING carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LFVN (Lifevantage Corporation (Delaware)) holds a C+ grade (67/100 RQD, P/E 7.5x, ROIC 29.2%, cap $73.9M) and MNOV (Medicinova Inc) posts a E grade (21/100 RQD, P/E 5.7x, ROIC -35.0%, cap $70.9M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while LFVN leads on capital efficiency (29.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CING?
▼
Per CING's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001862150), Cingulate Inc. generated $55.8M in revenue (+27.4% YoY), -$22.4M in net income, and -$17.4M in free cash flow against $15.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.03 (-0.01%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-10.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CING)Realized 20D OHLCV Swing Band: ±12%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY CING SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (26% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.72-4% Next Q
26
Q2 (-2Q)Grade E$4.53+22.1% Next Q
29
Q3 (-1Q)Grade E$5.53-9% Next Q
31
CurrentGrade E$5.03-8.7% Hist 90D α
34
Trajectory: E (26) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CING Turnaround Squeeze
While CING currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.00) and Max Pain ($5.28) forces dealer call-delta covering toward $12.48.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CING• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CING Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CING Stock advanced +1.00% Today — RQD Quant Desk Flash
Cingulate Inc. (CING) advanced +1.00% to $5.03, trading at 21% of its 52-week range ($3.16 – $11.89). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 21% of its 52-week range ($3.16 – $11.89) with RSI-14 at 53.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12% around $5.03 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CING Headlines & Catalysts
MARKET WIREYahoo Finance UK • 1d ago
Cingulate Inc. (CING) Seasonal returns chartYahoo Finance UK report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Alaunos Therapeutics (NASDAQ:TCRT), ScinaiBenzinga report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
CATALYSThttps://www.dars.gov.et/ • 2d ago
CING Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 6.87% - Core Business Growthhttps://www.dars.gov.et/ report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 47d ago
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging PharmaChief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size PharmaKANSAS CITY, Kan., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharm
MARKET WIREYahoo Finance • 76d ago
CING: Second Quarter ResultsBy John Vandermosten, CFA NASDAQ: CING READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ: CING) reported second quarter 2026 results on August 13 th , 2026. During the three-month period, the company generated n
RISK WATCHYahoo Finance • 82d ago
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial ReadinessCash and Cash Equivalents of $28.4 Million as of June 30, 2026 Providing Runway Through Mid-2027; Company Advances Chemistry, Manufacturing and Controls (CMC) Work Toward NDA ResubmissionKANSAS CITY, Kan., Aug. 13, 2026
CATALYSTYahoo Finance • 124d ago
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional InvestorsKANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical com
MARKET WIREYahoo Finance • 152d ago
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's latest update shifts the near-term CTx-1301 setup
RISK WATCHYahoo Finance • 154d ago
Cingulate Receives Complete Response Letter from FDA for CTx-1301No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related RequestsCompany Plans Prompt Response and Submission of Requested InformationCompany is Well Capitalized with
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CING)
- ✓Walkthrough of CING's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CING // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.00%▼ DESCENDING CHANNEL
2026-11-04O $4.98H $5.03L $4.98C $5.03VOL 107.7K
RES: $5.65SUP: $3.96SMA50: $5.00SMA200: $5.44
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CING Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +27.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on CING today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CING. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CING today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CING)
Health Care Rank #640 of 1015
⚔️ LFVN vs CING Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CING vs. LFVN, MNOV, CRBP, COYA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Cingulate Inc. (CING) ranks #640 by composite RQD confidence (34/100, grade E) and #691 by equity capitalization ($73.1M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while LFVN leads on capital efficiency and profitability with 29.2% ROIC and 80.4% gross margin. LFVN currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with CING at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CING
ACTIVE
Cingulate Inc. | E | 34/100 | — | — | -35.0% | +1.00% | $73.1M | Benchmark Subject |
| LFVN Lifevantage Corporation (Delaware) | C+ | 67/100 | 7.5x | 80.4% | 29.2% | -0.17% | $73.9M | /lfvn-vs-cing → |
| MNOV Medicinova Inc | E | 21/100 | 5.7x | — | -35.0% | +2.86% | $70.9M | /mnov-vs-cing → |
| CRBP Corbus Pharmaceuticals Holdings Inc. | E | 34/100 | — | — | -35.0% | -7.23% | $75.7M | /crbp-vs-cing → |
| COYA Coya Therapeutics Inc. | E | 29/100 | — | — | -35.0% | -10.53% | $75.8M | /coya-vs-cing → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001862150 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cingulate Inc. (CING) reported GAAP revenue of $55.8M (+27.4% vs. FY2024 revenue of $43.8M , and -12.4% cumulative change since FY2023) , GAAP net income of -$22.4M, operating cash flow of -$17.2M, and free cash flow of -$17.4M (+6.7% YoY). On the balance sheet, CING closed FY2025 with $15.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $55.8M | -$22.4M | -$17.2M | -$17.4M | $15.1M | — |
| FY2024 (FY) | 2024-12-31 | $43.8M | -$16.6M | -$18.5M | -$18.7M | $14.9M | — |
| FY2023 (FY) | 2023-12-31 | $63.7M | -$23.5M | -$15.0M | -$15.0M | — | — |
3. CING Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CING stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Cingulate Inc. (NASDAQ: CING) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $5.03 (+1.00% 1D, market cap $73.1M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CING ranks #640 in composite RQD confidence.
How does CING compare to LFVN and MNOV in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CING carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LFVN (Lifevantage Corporation (Delaware)) holds a C+ grade (67/100 RQD, P/E 7.5x, ROIC 29.2%, cap $73.9M) and MNOV (Medicinova Inc) posts a E grade (21/100 RQD, P/E 5.7x, ROIC -35.0%, cap $70.9M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while LFVN leads on capital efficiency (29.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CING?
Per CING's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001862150), Cingulate Inc. generated $55.8M in revenue (+27.4% YoY), -$22.4M in net income, and -$17.4M in free cash flow against $15.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CING trading relative to its 50-day, 200-day, and 52-week technical levels?
CING last traded at $5.03 (+1.00% on volume of 107,705 shares), positioning the stock +0.60% above its 50-day simple moving average ($5.00) and -7.54% below its 200-day simple moving average ($5.44). Across its 52-week range of $3.16 to $11.89, CING sits at the 21.4% percentile with a 14-day RSI of 53.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($4.43 to $5.63).
ROARABLE RATING BRIEF • RQD 34/100 (E)
✓ SEC XBRL & RQD VERIFIED
CING — Cingulate Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Cingulate Inc. (CING) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $5.03 (+1.00% 1D, market capitalization $73.1M).
- Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -23.06%.
- Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Cingulate Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,..1B. Reported revenue is — for each period shown.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cingulate Inc. (CING) reported $55.8M in annual revenue (up from $43.8M in FY2024, +27.4% YoY) and -$22.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($63.7M revenue, -$23.5M net income) through FY2025, CING scaled operating cash flow to -$17.2M and free cash flow to -$17.4M, backed by $15.1M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -23.06% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $3.16 – $11.89 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), CING carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can CING sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $55.8M and free cash flow of -$17.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is CING's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
CING Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Cingulate Inc. (CING) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Cingulate Inc. (CING) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 1d ago
Cingulate Inc. (CING) Seasonal returns chart Yahoo Finance UK report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 2d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Alaunos Therapeutics (NASDAQ:TCRT), Scinai Benzinga report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.dars.gov.et/ • 2d ago
CING Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 6.87% - Core Business Growth https://www.dars.gov.et/ report covering Cingulate Inc. (CING) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 47d ago
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size PharmaKANSAS CITY, Kan., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharm
🟡 MARKET WIRE Yahoo Finance • 76d ago
CING: Second Quarter Results By John Vandermosten, CFA NASDAQ: CING READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ: CING) reported second quarter 2026 results on August 13 th , 2026. During the three-month period, the company generated n
🔴 RISK WATCH Yahoo Finance • 82d ago
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness Cash and Cash Equivalents of $28.4 Million as of June 30, 2026 Providing Runway Through Mid-2027; Company Advances Chemistry, Manufacturing and Controls (CMC) Work Toward NDA ResubmissionKANSAS CITY, Kan., Aug. 13, 2026
🟢 CATALYST Yahoo Finance • 124d ago
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E® CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional InvestorsKANSAS CITY, Kan., July 02, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical com
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CING Bull vs. Bear Conversation Board — What's Your Call at $5.03?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CING 🐻 33% BEARISH CONVICTION
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH
🎯 Target: $6.08 (+22.1%)
📌 Pinned Debate A reported Q2 2026 narrower-than-expected loss lifted shares 6.87%, the only GREEN catalyst in the news wire.
Picked up a starter position in CING in my $100K Virtual Cash book at $4.98. A reported Q2 2026 narrower-than-expected loss lifted shares 6.87%, the only GREEN catalyst in the news wire.. Trading inside a $3.16–$11.89 52-week range with -23.06% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
CapAlloc_Nerd 🐂 BULL
@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH
🎯 Target: $3.83 (-23.1%)
Spot @ $4.98 Reported revenue is $0.0M in every period with ROIC at -35% and FCF yield at -23.06%.
Careful chasing CING at $4.98. Reported revenue is $0.0M in every period with ROIC at -35% and FCF yield at -23.06%.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $3.83 on multiple compression.